Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec noted that 100,000 patients have been treated with the drug since launch and emphasized that the only reported PML case occurred in a patient on long-term treatment despite having a known risk factor.